Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking β-catenin and cyclooxygenase-2

Molecular Cancer Therapeutics

Volumn 8, Issue 11, 2009, Pages 3046-3055

  Lim, Kyu ^a,c   Han, Chang ^a   Dai, Yifan ^b   Shen, Miaoda ^b   Wu, Tong ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; BETA CATENIN; CASPASE 3; CASPASE 9; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; ICOSAPENTAENOIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PREVENTION; CARCINOMA CELL; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPHOSPHORYLATION; DOWN REGULATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; UPREGULATION;

ANIMALS; APOPTOSIS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS, UNSATURATED; GLYCOGEN SYNTHASE KINASE 3; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; LITHIUM CHLORIDE; LIVER NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; WNT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70949100689     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0551     Document Type: Article

References (38)

1. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003;3:573-588
2. Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 2006;32:28-44.
3. Kondo M, Yamamoto H, Nagano H, et al. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 1999;5:4005-4012 (Pubitemid 30013777)
4. Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999;29:688-696 (Pubitemid 29109581)
5. Shiota G, Okubo M, Noumi T, et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999;46:407-412
6. Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001;7:1410-1418
7. Rahman MA, Dhar DK, Yamaguchi E, et al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001;7:1325-1332 (Pubitemid 32708688)
8. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003;38:756-768 (Pubitemid 37052162)
9. Cheng AS, Chan HL, To KF, et al. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int J Oncol 2004;24:853-860
10. Ikeda T, Tozuka S, Hasumura Y, Takeuchi J. Prostaglandin-E-producing hepatocellular carcinoma with hypercalcemia. Cancer 1988;61:1813-1814
11. Han C, Michalopoulos GK, Wu T. Prostaglandin E(2) receptor EP(1) transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 2006;207:261-270
12. Thompson MD, Monga SP. WNT/β-catenin signaling in liver health and disease. Hepatology 2007;45:1298-1305 (Pubitemid 46775794)
13. Monga SP. Hepaticadenomas: presumed innocent until proven to be β-catenin mutated. Hepatology 2006;43:401-404
14. Zucman-Rossi J, Jeannot E, Van Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006;43:515-524
15. Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000;24:245-250 (Pubitemid 30132191)
16. Branda M, Wands JR. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 2006;43:891-902.
17. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003;1653:1-24.
18. Colnot S, Decaens T, Niwa-Kawakita M, et al. Liver-targeted disruption of Apc in mice activates β-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A 2004;101:17216-17221
19. Merle P, de la Monte S, Kim M, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 2004;127:1110-1122
20. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-β-catenin signaling axis. Science 2005;310:1504-1510
21. Shao J, Jung C, Liu C, Sheng H. Prostaglandin E2 Stimulates the β-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 2005;280:26565-26572
22. Hardman WE. (n-3) fatty acids and cancer therapy. J Nutr 2004;134:3427-30S.
23. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary longchain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 2004;79:935-945
24. Xu L, Han C, Lim K, Wu T. Cross-talk between peroxisome proliferator-activated receptor δ and cytosolic phospholipase A(2) α/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells. Cancer Res 2006;66:11859-11868
25. Kang JX, Wang J, Wu L, Kang ZB. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature 2004;427:504.
26. Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005;280:3217-3223
27. Myung SJ, Rerko RM, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A 2006;103:12098-12102
28. Torbenson M, Lee JH, Choti M, et al. Hepaticadenomas: analysis of sex steroid receptor status and the Wnt signaling pathway. Mod Pathol 2002;15:189-196
29. Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the β-catenin gene. Cancer Res 1999;59:269-273 (Pubitemid 29048850)
30. Ogawa K, Yamada Y, Kishibe K, Ishizaki K, Tokusashi Y. β-catenin mutations are frequent in hepatocellular carcinomas but absent in adenomas induced by diethylnitrosamine in B6C3F1 mice. Cancer Res 1999;59:1830-1833 (Pubitemid 29186151)
31. Ranganathan S, Tan X, Monga SP. β-Catenin and met deregulation in childhood Hepatoblastomas. Pediatr Dev Pathol 2005;8:435-447 (Pubitemid 41586881)
32. Kang JX. From fat to fat-1: a tale of ω-3 fatty acids. J Membr Biol 2005;206:165-172
33. Smith WL. Cyclooxygenases, peroxide tone and the allure of fish oil. Curr Opin Cell Biol 2005;17:174-182
34. Calviello G, Di Nicuolo F, Gragnoli S, et al. n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1α induction pathway. Carcinogenesis 2004;25:2303-2310 (Pubitemid 39625169)
35. Hoppler S, Kavanagh CL. Wnt signalling: variety at the core. J Cell Sci 2007;120:385-393
36. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006;127:469-480
37. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006;281:22429-22433 (Pubitemid 44242270)
38. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and β-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5:691-701. (Pubitemid 39150127)